Answer
No adverse reactions have been identified for idarucizumab (Praxbind).
Sources for this answer
- Praxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim Limited · emc · SmPC §4.8 Undesirable effects · Version 12Document updated
Sources checked